At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Endoscopically Guided Ablationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
In Brief
A Phase 4 clinical trial evaluating Endoscopically Guided Ablation for Atrial Fibrillation. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to confirm the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact in the treatment of atrial fibrillation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesItaly
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedSep 2010
Primary CompletionMar 2012
Study CompletionJun 2012
TodayJul 2026
First PostedSep 9, 2010
Enrollment StartSep 1, 2010
Primary CompletionMar 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.8 years ago
Interventions
Endoscopically Guided Ablationdevice
Visually Guided Ablation using EAS-AC